Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).

Kucher, Nils; Aujesky, Drahomir; Beer, Jürg H; Mazzolai, Lucia; Baldi, Thomas; Banyai, Martin; Hayoz, Daniel; Kaeslin, Thomas; Korte, Wolfgang; Escher, Robert; Husmann, Marc; Frauchiger, Beat; Baumgartner, Iris; Spirk, David (2016). Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER). Thrombosis and haemostasis, 116(3), pp. 472-479. Schattauer 10.1160/TH16-03-0209

[img] Text
Rivaroxaban.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (252kB) | Request a copy

We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland were enrolled in the SWIss Venous ThromboEmbolism Registry (SWIVTER). Overall, 417 (20 %) patients were treated with rivaroxaban. In comparison to 1,645 patients on conventional anticoagulation, patients on rivaroxaban were younger (56 ± 18 vs. 65 ± 17 years; p<0.001), less often had pulmonary embolism (38 % vs 66 %; p<0.001), hypertension (26 % vs 41 %; p<0.001), cancer (10 % vs 28 %; p<0.001), congestive heart failure (10 % vs 17 %; p=0.001), diabetes (8 % vs 15 %; p<0.001), chronic lung disease (7 % vs 13 %; p=0.001), renal insufficiency (7 % vs 13 %; p=0.001), recent surgery (7 % vs 14 %; p<0.001), and acute coronary syndrome (1 % vs 4 %; p=0.009). VTE reperfusion therapy was more frequently used (28 % vs 9 %; p<0.001) and indefinite-duration anticoagulation treatment less often planned (26 % vs 39 %; p<0.001), respectively. In the propensity score-adjusted population, the risk of recurrent VTE was similar in patients on rivaroxaban vs conventional anticoagulation (1.2 % vs 2.1 %, hazard ratio [HR] 0.55, 95 % confidence interval [CI] 0.18-1.65; p=0.29); the risk of major bleeding was also similar, respectively (0.5 % vs 0.5 %, HR 1.00, 95 %CI 0.14-7.07; p=1.00). Conventional anticoagulation is still frequently used for the treatment of VTE, particularly in the elderly and those with comorbidities. Early clinical outcomes were comparable between propensity score-adjusted patient populations on rivaroxaban and conventional anticoagulation.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine

UniBE Contributor:

Kucher, Nils; Aujesky, Drahomir; Baumgartner, Iris and Spirk, David

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0340-6245

Publisher:

Schattauer

Language:

English

Submitter:

Catherine Gut

Date Deposited:

22 Mar 2017 11:28

Last Modified:

24 Mar 2017 13:47

Publisher DOI:

10.1160/TH16-03-0209

PubMed ID:

27346301

Uncontrolled Keywords:

Anticoagulation; rivaroxaban; venous thromboembolism

BORIS DOI:

10.7892/boris.93052

URI:

https://boris.unibe.ch/id/eprint/93052

Actions (login required)

Edit item Edit item
Provide Feedback